甘精胰岛素联合利拉鲁肽强化治疗对初诊T2DM患者的影响

Effect of Insulin Glargine Combined with Liraglutide Intensive Treatment on Newly Diagnosed T2DM Patients

目的:探究甘精胰岛素联合利拉鲁肽强化治疗对初诊2型糖尿病(T2DM)患者的影响。方法:选取2018年7月-2021年7月松滋市人民医院接受治疗的80例初诊T2DM患者。根据随机数字表法将其分为观察组和对照组,各40例。对照组给予常规治疗,观察组给予甘精胰岛素联合利拉鲁肽强化治疗。比较两组血糖达标及胰岛素使用情况,治疗前及治疗1个月后血糖相关指标、胰岛素相关指标,治疗前及治疗3周、1个月后体重指数(BMI),不良反应。结果:观察组一半例数血糖达标时间、整体血糖达标时间均早于对照组,胰岛素日用量少于对照组(P<0.05)。治疗1个月后,观察组空腹血糖(FPG)、餐后2 h血糖(2 h PG)、糖化血红蛋白(HbA1c)水平均低于对照组(P<0.05)。治疗1个月后,观察组稳态模型胰岛素抵抗指数(HOMA-IR)低于对照组,空腹胰岛素(FINS)水平高于对照组(P<0.05)。治疗3周、1个月后,观察组BMI低于对照组(P<0.05)。治疗1个月内,观察组不良反应发生率低于对照组(P<0.05)。结论:甘精胰岛素联合利拉鲁肽强化治疗初诊T2DM患者,能够快速控制血糖水平,减少胰岛素用量,改善胰岛素抵抗状况,具有临床推广价值。

Objective:To investigate the effect of Insulin Glargine combined with Liraglutide intensive treatment on first diagnosed type 2 diabetes mellitus (T2DM) patients.Method:A total of 80 first diagnosed T2DM patients who were treated in Songzi Municipal People’s Hospital from July 2018 to July 2021 were selected.According to the method of random number table,they were divided into observation group and control group,40 cases in each group.The control group was given routine treatment,and the observation group was given Insulin Glargine combined with Liraglutide intensive treatment.The blood glucose reaches the standard and insulin use condition,blood glucose related indexes and insulin related indexes before treatment and after 1 month of treatment,body mass index (BMI) before treatment,after 3 weeks and 1 month of treatment,and adverse reactions were compared between the two groups.Result:The time of reaching the standard of blood glucose in half cases and the time of reaching the standard of blood glucose in overall of the observation group were earlier than those in the control group,and the daily dosage of insulin was less than that in the control group (P<0.05).After 1 month of treatment,the fasting plasma glucose (FPG),2 h postprandial blood glucose (2 h PG) and glycosylated hemoglobin (HbA1c) levels in the observation group were lower than those in the control group (P<0.05).After 1 month of treatment,the homeostasismodel assessment for insulin resistance (HOMA-IR) of the observation group was lower than that of the control group,and fasting insulin (FINS) level was higher than that of the control group (P<0.05).After 3 weeks and 1 month of treatment,the BMI of the observation group were lower than those of the control group (P<0.05).Within 1 month of treatment,the incidence of adverse reactions in the observation group was lower than that in the control group (P<0.05).Conclusion:The Insulin Glargine combined with Liraglutide intensive treatment for first diagnosed T2DM patients can quickly control the blood glucose level,reduce the amount of insulin use,and improve the insulin resistance status,which has clinical promotion value.